Table 5.

Summary of TEAEs

		Baricitinib
	Placebo (N = 8)	2 mg (N = 8)	4 mg (N = 9)	10 mg (N = 8)	Overall (N = 33)
All causalities
Number of subjects (%) with ≥1 AE	4 (50.0)	1 (12.5)	2 (22.2)	4 (50.0)	11 (33.3)
Total number of TEAEs (all severities were “mild”), n	10	2	3	6	21
Drug related (number of TEAEs [number of subjects with TEAEs])
ECG abnormal	6 (2)	0	0	0	6 (2)
ALT increased	1 (1)	0	1 (1)	2 (2)	4 (4)
AST increased	1 (1)	0	1 (1)	1 (1)	3 (3)
Bilirubin increased	0	0	0	1 (1)	1 (1)
ANC decreased	0	0	1 (1)	0	1 (1)
Hypotension	1 (1)	0	0	0	1 (1)
Orthostatic hypotension, n	0	0	0	1 (1)	1 (1)
Overall	9 (4)	0 (0)	3 (2)	5 (4)	17 (10)

AEs, adverse events; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; ECG, electrocardiogram; TEAEs, treatment‐emergent adverse events.